HRT and Breast Cancer Risk: What Women Need to Know

For many women navigating perimenopause or menopause, considering hormone therapy can bring up an important question:

Could hormone therapy increase my risk of breast cancer?

It's a question I hear often, and it's completely understandable. You may have heard warnings about hormone replacement therapy (HRT) and breast cancer for years, particularly following the publication of a major study in 2002.

But the relationship between hormone therapy and breast cancer is more nuanced than a simple yes-or-no answer.

The type of hormone therapy, whether it contains oestrogen alone or oestrogen with a progestogen, how long it's used and your individual health history can all influence the discussion.

Understanding the evidence can help you feel more informed when discussing your options with your healthcare provider.

What Did the Women's Health Initiative Study Find?

In 2002, the Women's Health Initiative (WHI) published findings that significantly changed the conversation around menopausal hormone therapy.

One part of the study investigated combined hormone therapy using conjugated equine oestrogens and medroxyprogesterone acetate, a synthetic progestogen. The researchers found an increased incidence of breast cancer among women taking this combination compared with those taking a placebo.

The findings received widespread attention, and many women became concerned about the safety of hormone therapy.

However, there is an important detail to understand: the WHI investigated specific hormone formulations in specific groups of women.

The participants were aged 50 to 79, with an average age of approximately 63. Many were older than the women who typically seek treatment for perimenopausal symptoms.

The study also investigated two different treatment approaches:

• Oestrogen plus progestogen: This trial involved women who had an intact uterus and found an increased incidence of breast cancer with the specific combination studied.

• Oestrogen alone: This trial involved women who had undergone a hysterectomy. Long-term follow-up found a lower incidence of breast cancer among women assigned to conjugated equine oestrogens alone compared with placebo.

These results are important, but they need to be interpreted carefully. They relate to the specific treatments and populations studied, and they do not establish that all forms of oestrogen are protective or that all combined hormone therapies carry identical risks.

Does All Hormone Therapy Increase Breast Cancer Risk?

No single answer applies to every form of menopausal hormone therapy.

The relationship between MHT and breast cancer depends on several factors, including the type of therapy, duration of use and individual risk profile.

Oestrogen-only Therapy

Oestrogen-only MHT is generally prescribed to women who have had a hysterectomy.

In the WHI trial, oestrogen-only therapy was associated with a lower incidence of breast cancer during long-term follow-up. This differs from the findings for the combined therapy studied in women with an intact uterus.

However, these findings should not be interpreted as proof that oestrogen-only therapy reduces breast cancer risk for every woman or is suitable for everyone.

Combined Oestrogen and Progestogen Therapy

Women who have an intact uterus generally need a progestogen alongside systemic oestrogen to protect the lining of the uterus from the effects of unopposed oestrogen.

Research has found that combined MHT can be associated with an increased risk of breast cancer, with risk influenced by the formulation and duration of use.

This is why the choice of progestogen, the treatment regimen and the length of treatment are important parts of the conversation.

Your healthcare provider can help you understand the potential benefits and risks of the options available to you.

What About Body-Identical Progesterone?

You may have heard the terms body-identical or bioidentical hormones when researching menopause treatment.

These terms can be confusing because they are sometimes used to describe different products.

Body-identical hormones have the same molecular structure as hormones naturally produced by the body. Some regulated medicines, including oestradiol and micronised progesterone, fall into this category.

However, being body-identical does not automatically mean a treatment is risk-free.

Researchers have investigated whether micronised progesterone may have a different breast cancer risk profile from certain synthetic progestogens, including medroxyprogesterone acetate.

Some observational research has suggested differences between these formulations. However, the evidence is not sufficient to conclude that micronised progesterone eliminates breast cancer risk or that every body-identical hormone preparation is safer than every alternative.

It is also important to distinguish regulated, approved medicines from compounded bioidentical hormone preparations, for which evidence of safety and effectiveness may be limited.

The most appropriate option depends on your circumstances, the treatment being considered and the available evidence.

Does It Matter When You Start Hormone Therapy?

Timing is another consideration when discussing MHT.

Research has explored whether starting hormone therapy closer to the onset of menopause produces a different balance of benefits and risks compared with starting it later.

For healthy women who are younger than 60 or within 10 years of menopause onset, the overall benefit-risk balance of MHT is generally more favourable when treatment is being considered for bothersome menopausal symptoms and there are no contraindications.

However, this does not mean that starting hormone therapy earlier removes the risk of breast cancer.

The timing of treatment is one part of an individual assessment. Your symptoms, medical history, cardiovascular health, breast cancer risk and the specific treatment being considered all matter.

There is no single age or time point that makes hormone therapy automatically appropriate for everyone.

Do Patches and Gels Carry a Lower Breast Cancer Risk?

You may also have heard that transdermal oestrogen, delivered through the skin using a patch or gel, is safer than oral oestrogen.

The route of administration does matter for some health outcomes. For example, transdermal oestrogen is generally associated with a lower risk of venous blood clots than oral oestrogen. However, this should not be confused with proof that patches or gels carry a lower breast cancer risk.

Breast cancer risk needs to be considered separately from risks such as blood clots and stroke. Similarly, different delivery methods do not automatically make a hormone preparation safer or more effective.

Your clinician can explain the evidence for the particular treatment being considered and why one route may be appropriate for you.

What If You Have a Family History of Breast Cancer?

A family history of breast cancer can understandably make decisions about MHT feel more complicated.

Having a relative who has had breast cancer does not automatically mean that you will develop it yourself, nor does it automatically determine whether hormone therapy is appropriate.

Your personal risk depends on several factors, which may include:

• The number of relatives who have had breast cancer

• Whether they are first-degree relatives, such as your mother, sister or daughter

• The age at which relatives were diagnosed

• Your own breast health and medical history

• Any known inherited genetic risk factors

• Your age and other individual risk factors

Depending on your history, your healthcare provider may recommend a formal breast cancer risk assessment or referral for specialist advice.

The aim is to understand your individual circumstances rather than making decisions based on family history alone.

What If You've Had Breast Cancer?

For women with a personal history of breast cancer, decisions about hormone treatment require particular care.

Systemic MHT is generally avoided after breast cancer, especially when the cancer is hormone-sensitive, because exposure to oestrogen or progestogens may be a concern depending on the cancer and treatment history.

For women experiencing significant menopausal symptoms after breast cancer treatment, there may be non-hormonal options worth exploring.

Low-dose vaginal oestrogen may also be considered in selected circumstances for persistent genitourinary symptoms when non-hormonal treatments have not been effective. This requires an individual discussion with the treating clinician and, where appropriate, the breast cancer specialist, particularly for women taking aromatase inhibitors.

A history of breast cancer should never be managed through general hormone advice alone. Your oncology team and healthcare provider can help you understand which options may be appropriate for your circumstances.

How Can You Make an Informed Decision About MHT?

Deciding whether to use hormone therapy is personal. It should involve a clear discussion of your symptoms, health history, preferences and the potential benefits and risks of treatment.

Before making a decision, it may help to discuss:

• Which symptoms are affecting your quality of life

• Whether MHT is appropriate for your stage of menopause

• The differences between oestrogen-only and combined therapy

• Which progestogen may be appropriate if you have a uterus

• Your personal and family history of breast cancer

• Other health considerations, including cardiovascular and blood clot risk

• The expected benefits, possible side effects and uncertainties

• How long treatment may be needed and when it should be reviewed

You should also discuss appropriate breast screening based on your age and individual risk.

MHT is not suitable for everyone, and not every woman needs it. Equally, concerns about breast cancer should be explored through an informed conversation rather than relying on a single headline or a generalised statement about all hormone treatments.

Looking at the Whole Picture

There is no single hormone therapy that is right for every woman.

The evidence surrounding MHT and breast cancer is complex, but that does not mean you need to navigate it alone.

Understanding the difference between oestrogen-only and combined therapy, the role of progestogens, the timing of treatment and your own risk factors can help you make a more informed decision.

At My Menopause Clinic Australia, the focus is on understanding your symptoms, health history and goals, then discussing options in the context of current evidence and your individual circumstances.

You deserve clear information, the opportunity to ask questions and care that takes your concerns seriously.

If you're considering hormone therapy or have concerns about breast cancer risk, book a consultation to discuss your individual circumstances and explore the options that may be appropriate for you.

Together, we can look at the whole picture and help you make an informed decision about your menopause care.